This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bushe, C. Articles by Paton, C. Search for Related Content PubMed PubMed Citation Articles by Bushe, C. Articles by Paton, C. Social Bookmarking                         What's this?

The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?

Eli Lilly and Company Limited, Basingstoke, UK, bushe_chris{at}lilly.com

Carol Paton

Chief Pharmacist, Oxleas NHS Trust, Dartford, UK

Lipid abnormalities are common in the general population and early data suggests that they may be more common in people with schizophrenia. Little data exist from treatment-naive patients making it difficult to differentiate any genetic contribution associated with a diagnosis of schizophrenia from the lifestyle risks associated with this diagnosis. Additional potential risks associated with antipsychotic drug treatment have been noted in the literature since 1971. The majority of the existing data on lipids derive from retrospective and cross-sectional analyses of datasets that have been designed for other purposes. Specifically screening bias for lipid testing and treatment selection bias are important potential confounders. Prospective clinical trials are difficult to interpret, as many are short-term, report on non-fasting data and were never designed to evaluate the differential effects of antipsychotic drugs on lipids as a primary endpoint. There is little reported data on lipid fractions such as LDL and HDL. Nevertheless there is some evidence from placebo-controlled studies that antipsychotics may be differentially associated with a small, clinically insignificant increase in cholesterol and a larger, potentially clinically significant increase in triglycerides.

Further prospective randomized trials, using fasting data and controlling for established risk factors such as diet and exercise are essential to determine if there are clinically meaningful differential effects on lipids associated with individual antipsychotic drugs.

Key Words: lipids • schizophrenia • typical antipsychotics • atypical antipsychotics • hyperlipidaemia • dyslipidaemia

Journal of Psychopharmacology, Vol. 19, No. 6 suppl, 76-83 (2005)
DOI: 10.1177/0269881105058719


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?